Table 1.
Patient baseline demographic, clinical test scores, and regional [18F]FDDNP binding.
| Variable | Escitalopram + Memantine (n=11) | Escitalopram + placebo (n=11) | Statistic |
|---|---|---|---|
| Median (range) | Median (range) | Kruskal-Wallis Test | |
| Age (years) | 65 (63-83) | 75 (63-82) | χ2 (1) = 1.57, p = .2 |
| Education | 14 (12-18) | 16 (13-25) | χ2 (1) = 1.02, p = .3 |
| Age of onset | 55 (13-77) | 63.5 (8-80) | χ2 (1) = 1.12, p = .3 |
| Number of episodes | 2 (1-12) | 6 (1-25) | χ2 (1) = 1.38, p = .2 |
| MMSE | 28 (25-30) | 28 (23-30) | χ2 (1) = 0.88, p = .4 |
| HAM-D | 18 (16-21) | 16 (16-19) | χ2 (1) = 2.88, p = .09 |
| Z-scores | |||
| Delayed recall | 0.19 (−0.78-1.42) | -0.13 (−1.47-.99) | χ2 (1) = 0.57, p = .5 |
| Executive function | 0.21 (−1.39-0.71) | -0.02 (−1.29-0.79) | χ2 (1) = 0.01, p = .9 |
| [18F]FDDNP DVRs | |||
| Frontal | 1.15 (1.06-1.22) | 1.15 (1.06-1.26) | χ2 (1) = 0.002, p = 1.0 |
| Parietal | 1.08 (1.03-1.16) | 1.09 (1.0-1.15) | χ2 (1) = 0.001, p = 1.0 |
| MTL | 1.22 (1.02-1.35) | 1.22 (1.03-1.42) | χ2 (1) = 0.67, p = .4 |
| Treatment groups | |||
| N (%) | N (%) | Fisher’s exact | |
| Male | 8 (73) | 6 (55) | p = .7 |
| Female | 3 (27) | 5 (45) | |
| MCI | 1 (9) | 1 (9) | p = 1.0 |